// App-Quantinova.ai

5052 : A phase II study evaluating the efficacy of enzalutamide and the role of ARv7 in metastatic castration-resistant prostate cancer (mCRPC) patients (pts) with visceral disease.

Researchers

Presenter

  • Pierangela Sepe

Principal Investigators

  • Giuseppe Procopio

  • Umberto Basso

  • Orazio Caffo

  • Vera Cappelletti

  • Melanie Claps

  • Ugo De Giorgi

  • Lucia Fratino

  • Valentina Guadalupi

  • Patrizia Miodini

  • Bruno Perrucci

  • Alessia Mennitto

  • Daniele Santini

  • Francesco Spina

  • Arianna Ottini

  • Filippo G. De Braud

  • Elena Verzoni

Medical Centers

  • Department of Medical Oncology, IRCCS Fondazione Istituto Nazionale dei Tumori, Milan, Italy

  • Medical Oncology Unit 1, Department of Oncology, Istituto Oncologico Veneto IOV IRCCS, Padua, Italy

  • Santa Chiara Hospital, Trento, Italy

  • Department of Applied Research and Technological Development, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy

  • Department of Medical Oncology, Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori (IRST) IRCCS, Meldola, Italy

  • Dipartimento di Oncologia Medica, Centro di Riferimento Oncologico di Aviano (CRO), IRCCS, Aviano, Italy

  • Department of Applied Research and Technological Development, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy

  • Oncology Department, ASST Istituti Ospitalieri, Viale Concordia 1, Cremona, Italy

  • Division of Oncology, University Hospital Maggiore della Carità, Italy

  • Italy

  • Department of Medical Oncology, Universita Campus Bio-Medico, Rome, Rome, Italy

  • Department of Hematology & Oncology, Niguarda Cancer Center, Ospedale Niguarda Ca' Granda, Milano, Italy

  • Division of Medical Oncology, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy

  • Medical Oncology Department, ENETS Center of Excellence, Fondazione IRCCS Istituto Nazionale dei Tumori and Oncology and Hemato-oncology Department, University of Milan, Milan, Italy

Locations

  • Italy

Companies

  • N/A

Study Components

Therapeutic Area

  • Oncology (ONC)

  • Urology

Disease

  • Metastatic castration-resistant prostate cancer

Biomarkers

  • Circulating tumor cells

  • Prostate specific antigen

Drug/Treatment

  • Enzalutamide

  • Docetaxel

Outcome

  • N/A

Study Design

  • Open Label

  • Multicenteric

Phase

  • II

Study Id's

  • NCT03103724

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved